Company
Headquarters: Huzhou, China
Employees: 1,591
CN¥7.40 Billion
CNY as of Jan. 1, 2024
US$1.04 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells colloidal gold tests, urinalysis strips, raw materials, instruments, and molecular diagnosis products primarily in China. Its products include genetic diagnosis products; colloidal gold rapid diagnostic tests for drugs of abuse, infectious diseases, fertility, cardiac and tumor markers, and autoimmunity; dry chemical strips; bio-liquid diagnostic kits; clinical test instruments; POCT time-resolved fluor immunoassay test kits; raw materials; etc. The company also exports its products to North and South America, Europe, South Asia, Southeast Asia, the Middle East, Africa, Russia, and Australia. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Zhejiang Orient Gene Biotech Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688298 wb_incandescent